Skip to main content
Log in

Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study

  • Original Article
  • Published:
Sleep and Breathing Aims and scope Submit manuscript

Abstract

Purpose

Evidence-based medicine promotes the current best evidence from clinical trials to guide decisions for individual patients. We assessed whether chronic obstructive pulmonary disease (COPD) patients included in exercise training studies and pharmacologic trials match those from a non-selected COPD target population sample.

Methods

Exercise training studies were identified in a literature search. Towards a Revolution in COPD Health (TORCH) and Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) were chosen to represent pharmacologic trials. Burden of Obstructive Lung Disease (BOLD) data were used to characterize target COPD population (BOLD target), defined as the presence of dyspnea (modified Medical Research Council ≥2) and non-reversible airway obstruction (post-bronchodilator FEV1/FVC ≤0.7 and FEV1% predicted ≤70 %).

Results

Overall 240 exercise training studies with 13,901, TORCH and UPLIFT with 12,105, and BOLD with 16,218 participants were evaluated. Males were overrepresented in exercise training studies (67.5 %) and pharmacologic trials (TORCH 75.8 %; UPLIFT 74.6 %), whereas in BOLD target 55.8 % were males (p < 0.001). In exercise training studies, 7.2 % were never-smokers, 0.0 % in TORCH and UPLIFT, but 36.0 % in BOLD target (p < 0.001). Subjects with cardiac comorbidity were excluded from 75.4 % of exercise training studies, entirely from TORCH and UPLIFT, but comprised 24.5 % of BOLD target.

Conclusions

COPD patients recruited in exercise training studies and in pharmacologic trials differ from target population of symptomatic COPD. Females, never-smokers, and patients with cardiac comorbidities are more likely excluded from the clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187(4):347–365. doi:10.1164/rccm.201204-0596PP

    Article  CAS  PubMed  Google Scholar 

  2. Mullerova H, Agusti A, Erqou S, Mapel DW (2013) Cardiovascular comorbidity in COPD: systematic literature review. Chest 144(4):1163–1178. doi:10.1378/chest. 12-2847

    Article  PubMed  Google Scholar 

  3. Maclay JD, MacNee W (2013) Cardiovascular disease in COPD: mechanisms. Chest 143(3):798–807. doi:10.1378/chest. 12-0938

    Article  CAS  PubMed  Google Scholar 

  4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-0

    Article  PubMed  Google Scholar 

  5. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T (2006) American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 173(12):1390–1413. doi:10.1164/rccm.200508-1211ST

    Article  PubMed  Google Scholar 

  6. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn't. BMJ 312(7023):71–72

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, The TORCH Investigators (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356(8):775–789. doi:10.1056/NEJMoa063070

    Article  CAS  PubMed  Google Scholar 

  8. The UPLIFT Study Investigators, Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359(15):1543–1554. doi:10.1056/NEJMoa0805800

    Article  Google Scholar 

  9. Vestbo J (2004) The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 24(2):206–210

    Article  CAS  PubMed  Google Scholar 

  10. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E (2007) International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 370(9589):741–750. doi:10.1016/S0140-6736(07)61377-4

    Article  PubMed  Google Scholar 

  11. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, for the TORCH investigators (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356(8):775–789. doi:10.1056/NEJMoa063070

    Article  CAS  PubMed  Google Scholar 

  12. Miravitlles M, Anzueto A (2009) Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulm Dis 4:185–201

    CAS  Google Scholar 

  13. Van Spall HG, Toren A, Kiss A, Fowler RA (2007) Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297(11):1233–1240. doi:10.1001/jama.297.11.1233

    Article  PubMed  Google Scholar 

  14. Niederseer D, Thaler CW, Niederseer M, Niebauer J (2013) Mismatch between heart failure patients in clinical trials and the real world. Int J Cardiol 168(3):1859–1865. doi:10.1016/j.ijcard.2012.12.069

    Article  PubMed  Google Scholar 

  15. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J (2002) Impact of COPD in North America and Europe in 2000: subjects' perspective of confronting COPD international survey. Eur Respir J 20(4):799–805

    Article  CAS  PubMed  Google Scholar 

  16. Celli BR, MacNee W (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23(6):932–946

    Article  CAS  PubMed  Google Scholar 

  17. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, Studnicka M, Bateman E, Anto JM, Burney P, Mannino DM, Buist SA (2011) COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 139(4):752–763. doi:10.1378/chest.10-1253

    Article  PubMed Central  PubMed  Google Scholar 

  18. Eltom S, Stevenson C, Birrell MA (2013) Unit 5.64. Chapter 5: Cigarette smoke exposure as a model of inflammation associated with COPD. In: Enna SJ et al. (eds) Current protocols in pharmacology. doi:10.1002/0471141755.ph0564s60

  19. Roth M (2008) Pathogenesis of COPD. Part III. Inflammation in COPD. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 12(4):375–380

    CAS  Google Scholar 

  20. Sin DD, Man SF (2005) Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2(1):8–11. doi:10.1513/pats.200404-032MS

    Article  PubMed  Google Scholar 

  21. European Heart Failure Training Group (1998) Experience from controlled trials of physical training in chronic heart failure. Protocol and patient factors in effectiveness in the improvement in exercise tolerance. Eur Heart J 19(3):466–475.

    Article  Google Scholar 

  22. Studnicka M, McBurnie M, Tan W, Gulsvik A, Gislason T, Kocabas A, Bateman E, Jithoo A, Janson C, Jenkins C, Welte T, Mejza F, Lamprecht B, Wouters E, Buist A (2011) The prevalence of reported cardiovascular disease in subjects with non-reversible airways obstruction—findings from the multi-center population-based burden of obstructive lung disease (BOLD) study. Am J Respir Crit Care Med 183:A5617

    Google Scholar 

  23. Schneider C, Bothner U, Jick SS, Meier CR (2010) Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 25(4):253–260. doi:10.1007/s10654-010-9435-7

    Article  PubMed  Google Scholar 

  24. Singh S, Loke YK, Enright PL, Furberg CD (2011) Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 342:d3215. doi:10.1136/bmj.d3215

    Article  PubMed Central  PubMed  Google Scholar 

  25. Karner C, Chong J, Poole P (2012) Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 7:Cd009285. doi:10.1002/14651858.CD009285.pub2

    PubMed  Google Scholar 

  26. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS (2013) Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 68(1):48–56. doi:10.1136/thoraxjnl-2012-201926

    Article  PubMed  Google Scholar 

  27. Loke YK, Singh S (2012) Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date. Ther Adv Drug Saf 3(3):123–131. doi:10.1177/2042098612438388

    Article  PubMed Central  PubMed  Google Scholar 

  28. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P (2013) Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 369(16):1491–1501. doi:10.1056/NEJMoa1303342

    Article  CAS  PubMed  Google Scholar 

  29. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326. doi:10.1056/NEJMoa1307684

    Article  CAS  PubMed  Google Scholar 

  30. Hiatt WR, Kaul S, Smith RJ (2013) The cardiovascular safety of diabetes drugs—insights from the rosiglitazone experience. N Engl J Med 369(14):1285–1287. doi:10.1056/NEJMp1309610

    Article  CAS  PubMed  Google Scholar 

  31. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327–1335. doi:10.1056/NEJMoa1305889

    Article  CAS  PubMed  Google Scholar 

  32. Lee SJ, Kavanaugh A (2004) A need for greater reporting of socioeconomic status and race in clinical trials. Ann Rheum Dis 63(12):1700–1701. doi:10.1136/ard.2003.019588

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Gershon AS, Dolmage TE, Stephenson A, Jackson B (2012) Chronic obstructive pulmonary disease and socioeconomic status: a systematic review. COPD 9(3):216–226. doi:10.3109/15412555.2011.648030

    Article  PubMed  Google Scholar 

  34. Janson C, Marks G, Buist S, Gnatiuc L, Gislason T, McBurnie MA, Nielsen R, Studnicka M, Toelle B, Benediktsdottir B, Burney P (2013) The impact of COPD on health status: findings from the BOLD study. Eur Respir J 42(6):1472–1483. doi:10.1183/09031936.00153712

    Article  PubMed Central  PubMed  Google Scholar 

  35. Taylor R, Dawson S, Roberts N, Sridhar M, Partridge MR (2007) Why do patients decline to take part in a research project involving pulmonary rehabilitation? Respir Med 101(9):1942–1946. doi:10.1016/j.rmed.2007.04.012

    Article  PubMed  Google Scholar 

  36. Herland K, Akselsen JP, Skjonsberg OH, Bjermer L (2005) How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 99(1):11–19

    Article  PubMed  Google Scholar 

  37. Travers J, Marsh S, Caldwell B, Williams M, Aldington S, Weatherall M, Shirtcliffe P, Beasley R (2007) External validity of randomized controlled trials in COPD. Respir Med 101(6):1313–1320. doi:10.1016/j.rmed.2006.10.011

    Article  PubMed  Google Scholar 

  38. Martin RJ, Chisholm AM, Price D (2014) The Arch conference declaration. Helping to further the science of pragmatic research. Ann Am Thorac Soc 11(Suppl 2):S83–S84. doi:10.1513/AnnalsATS.201308-256RM

    Article  PubMed  Google Scholar 

  39. Wong GW, Miravitlles M, Chisholm A, Krishnan J (2014) Respiratory guidelines–which real world? Ann Am Thorac Soc 11(Suppl 2):S85–S91. doi:10.1513/AnnalsATS.201309-298RM

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflicts of interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Josef Niebauer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niederseer, D., Richter, S.A.M., Neunhäuserer, D. et al. Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study. Sleep Breath 19, 801–808 (2015). https://doi.org/10.1007/s11325-014-1087-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11325-014-1087-5

Keywords

Navigation